Westfield Capital Management Co. LP Buys 9,584 Shares of Bio-Rad Laboratories, Inc. (NYSE:BIO)

Westfield Capital Management Co. LP lifted its holdings in Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) by 3.9% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 252,769 shares of the medical research company's stock after acquiring an additional 9,584 shares during the period. Westfield Capital Management Co. LP owned 0.90% of Bio-Rad Laboratories worth $84,571,000 at the end of the most recent quarter.

Several other institutional investors have also modified their holdings of BIO. UMB Bank n.a. boosted its position in shares of Bio-Rad Laboratories by 140.6% during the third quarter. UMB Bank n.a. now owns 77 shares of the medical research company's stock valued at $26,000 after buying an additional 45 shares during the period. Capital Advisors Ltd. LLC grew its position in Bio-Rad Laboratories by 193.8% during the 2nd quarter. Capital Advisors Ltd. LLC now owns 94 shares of the medical research company's stock worth $26,000 after purchasing an additional 62 shares during the last quarter. Gladius Capital Management LP purchased a new position in shares of Bio-Rad Laboratories in the third quarter worth about $32,000. EntryPoint Capital LLC acquired a new stake in shares of Bio-Rad Laboratories in the first quarter worth $51,000. Finally, Headlands Technologies LLC acquired a new position in shares of Bio-Rad Laboratories in the 2nd quarter valued at $51,000. 65.24% of the stock is owned by institutional investors.

Bio-Rad Laboratories Stock Up 2.3 %

NYSE BIO traded up $7.33 during mid-day trading on Friday, reaching $332.91. 184,506 shares of the company's stock traded hands, compared to its average volume of 217,893. The company has a fifty day simple moving average of $340.52 and a 200-day simple moving average of $316.27. Bio-Rad Laboratories, Inc. has a 1-year low of $262.12 and a 1-year high of $387.99. The company has a market cap of $9.32 billion, a price-to-earnings ratio of -12.18 and a beta of 0.93. The company has a current ratio of 6.14, a quick ratio of 4.52 and a debt-to-equity ratio of 0.16.

Bio-Rad Laboratories (NYSE:BIO - Get Free Report) last announced its quarterly earnings data on Wednesday, October 30th. The medical research company reported $2.01 earnings per share for the quarter, beating analysts' consensus estimates of $1.16 by $0.85. The business had revenue of $649.70 million during the quarter, compared to the consensus estimate of $628.18 million. Bio-Rad Laboratories had a negative net margin of 30.18% and a positive return on equity of 3.74%. The company's revenue for the quarter was up 2.8% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $2.33 EPS. As a group, equities research analysts expect that Bio-Rad Laboratories, Inc. will post 9.93 EPS for the current year.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on BIO. Citigroup lifted their price objective on Bio-Rad Laboratories from $400.00 to $450.00 and gave the stock a "buy" rating in a report on Thursday, October 31st. StockNews.com raised Bio-Rad Laboratories from a "hold" rating to a "buy" rating in a report on Friday, November 1st. Wells Fargo & Company started coverage on Bio-Rad Laboratories in a report on Tuesday, August 27th. They set an "equal weight" rating and a $340.00 price objective on the stock. Finally, Royal Bank of Canada boosted their price objective on Bio-Rad Laboratories from $446.00 to $469.00 and gave the company an "outperform" rating in a research note on Thursday, October 31st. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $391.80.

Insiders Place Their Bets

In other news, EVP James Barry sold 623 shares of Bio-Rad Laboratories stock in a transaction on Wednesday, September 4th. The stock was sold at an average price of $330.49, for a total transaction of $205,895.27. Following the transaction, the executive vice president now owns 147 shares in the company, valued at approximately $48,582.03. The trade was a 80.91 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, COO Andrew J. Last sold 3,000 shares of Bio-Rad Laboratories stock in a transaction dated Friday, September 6th. The shares were sold at an average price of $329.94, for a total value of $989,820.00. Following the transaction, the chief operating officer now directly owns 7,559 shares in the company, valued at approximately $2,494,016.46. This trade represents a 28.41 % decrease in their position. The disclosure for this sale can be found here. 17.06% of the stock is owned by company insiders.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.